OGN - Organon & Co.
After hours:
| Previous close | 19.45 |
| Open | 19.65 |
| Bid | 19.50 x 900 |
| Ask | 20.00 x 900 |
| Day's range | 19.56 - 19.88 |
| 52-week range | 18.87 - 38.09 |
| Volume | |
| Avg. volume | 2,063,180 |
| Market cap | 5.04B |
| Beta (5Y monthly) | 0.72 |
| PE ratio (TTM) | 6.63 |
| EPS (TTM) | 2.98 |
| Earnings date | 04 May 2023 |
| Forward dividend & yield | 1.12 (5.76%) |
| Ex-dividend date | 12 May 2023 |
| 1y target est | 31.14 |
Business WireOrganon Reports Results for the First Quarter Ended March 31, 2023
JERSEY CITY, N.J., May 04, 2023--Organon Reports Results for the First Quarter Ended March 31, 2023
ZacksAnalysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Business WireOrganon To Report First Quarter and Host Conference Call on May 4, 2023
JERSEY CITY, N.J., April 20, 2023--Organon To Report First Quarter and Host Conference Call on May 4, 2023
PR NewswireLifezone Metals launches off-take marketing process for nickel, copper and cobalt from the Kabanga nickel project
Lifezone Holdings Limited ("Lifezone Metals") has previously announced entry into a Business Combination Agreement with GoGreen Investments Corporation (NYSE: GOGN), a publicly traded company on the NYSE ("GoGreen"). Today, Lifezone Metals is pleased to announce that it has commenced an off-take marketing process with respect to the nickel, copper and cobalt from the Kabanga nickel project (the "Kabanga Project"), which Lifezone Metals believes comprises one of the world's largest and highest-gr
Business WireOrganon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
JERSEY CITY, N.J., March 07, 2023--Organon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
Business WireOrganon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022
JERSEY CITY, N.J., February 16, 2023--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2022.
PR NewswireAhead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's Health
For far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought. For the second consecutive year, the company is also providing its employees, including over 400
Business WireOrganon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
JERSEY CITY, N.J., February 06, 2023--Organon (NYSE: OGN), a global women’s healthcare company will release its fourth quarter and full year 2022 financial results on February 16, 2023, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST.
ZacksWill Organon (OGN) Beat Estimates Again in Its Next Earnings Report?
Organon (OGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Business WireOrganon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
JERSEY CITY, N.J., January 05, 2023--Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
Business WireOrganon To Present at the 41st Annual J.P. Morgan Healthcare Conference
JERSEY CITY, N.J., December 15, 2022--Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewswireDaré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
DARE-PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include: Two Additional Portfolio Programs (DARE-GML and grant-funded DARE-LBT); License Agreement with Organon to Commercialize XACIATO™; Ovaprene® IDE Approval for Pivotal Contraceptive Efficacy Study; Positive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1 2023 Anticipated Milestones Include: XACIATO First
Business WireOrganon Appoints Kirke Weaver as General Counsel and Corporate Secretary
JERSEY CITY, N.J., December 12, 2022--Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
Business WireOrganon To Present at the Piper Sandler 34th Annual Healthcare Conference
JERSEY CITY, N.J., November 15, 2022--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29th, 2022 at 9:00 a.m. EST.
Business WireOrganon Reports Results for the Third Quarter Ended September 30, 2022
JERSEY CITY, N.J., November 03, 2022--Organon reports results for the third quarter ended September 30, 2022
Business WireOrganon To Report Third Quarter Results and Host Conference Call on November 3, 2022
JERSEY CITY, N.J., October 20, 2022--Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
Business WireSamsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
INCHEON, Korea & JERSEY CITY, N.J., August 17, 2022--Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
Simply Wall St.Organon (NYSE:OGN) Is Paying Out A Dividend Of $0.28
Organon & Co.'s ( NYSE:OGN ) investors are due to receive a payment of $0.28 per share on 15th of September. This means...
Business WireOrganon Reports Results for the Second Quarter Ended June 30, 2022
JERSEY CITY, N.J., August 04, 2022--Organon reports results for the second quarter ended June 30, 2022
Business WireOrganon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
JERSEY CITY, N.J., July 28, 2022--Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
- Simply Wall St.
What Kind Of Shareholders Hold The Majority In Organon & Co.'s (NYSE:OGN) Shares?
If you want to know who really controls Organon & Co. ( NYSE:OGN ), then you'll have to look at the makeup of its share...
Business WireOrganon To Report Second Quarter Results and Host Conference Call on August 4, 2022
JERSEY CITY, N.J., July 21, 2022--Organon will release its second quarter 2022 financial results on 8/4/22, prior to the company’s webcast and call scheduled for 8:30 a.m. EDT.
PR NewswireCognizant Teams Up with Organon to Speed Delivery of Pharmaceutical Products and Improve Women's Healthcare
Cognizant (NASDAQ: CTSH) today announced it has signed a new multi-year agreement with Organon (NYSE: OGN), a global women's health company, to help improve the company's delivery of healthcare products and crucial medicinal supply chain management.
- GlobeNewswire
Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
Daré will receive a $10 million upfront payment from Organon An estimated 21 million American women experience bacterial vaginosis SAN DIEGO, June 30, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the exclusive license agreement entered into on March 31, 2022 with Organon (NYSE: OGN), a global women’s healthcare company, has become fully effective. Under the agreement, Organon licensed global rights to XACIATO (clindamy
Business WireOrganon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
JERSEY CITY, N.J., June 13, 2022--Organon announces first biosimilars business deal with a global license agreement with Henlius.